MTSR Metsera, Inc.

Nasdaq metsera.com


$ 77.12 $ 0.00 (0 %)    

Thursday, 06-Nov-2025 05:12:50 EST
QQQ $ 623.70 $ 0.00 (0 %)
DIA $ 472.94 $ 0.00 (0 %)
SPY $ 677.97 $ 0.00 (0 %)
TLT $ 89.12 $ 0.00 (0 %)
GLD $ 368.48 $ 0.00 (0 %)
$ 71.38
$ 72.00
$ 77.12 x 14
$ 77.28 x 3
-- - --
$ 12.30 - $ 74.42
8,441,211
na
7.49B
$ 2.46
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-28-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-26-2025 12-31-2024 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://www.ft.com/content/ae3297f3-4dd1-4c8a-b9c5-9c3717d34c52 

Core News & Articles

"Metsera is gratified by the Delaware Court of Chancery's decision to deny Pfizer's request for a temporary restrai...

Core News & Articles

-Reuters Citing FTC Letter To Metsera

Core News & Articles

-Reuters Citing Metsera Letter To Court

Core News & Articles

-Reuters Citing Letter To Court

 novo-pfizer-are-battling-to-buy-the-future-of-weight-loss--but-viking-already-owns-it

Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nor...

 pfizer-novo-nordisk-intensify-fight-for-metsera-as-buyout-offers-continue-to-climb

Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escala...

Core News & Articles

-Reuters Citing Conf. Call

Core News & Articles

 - Reuters Citing Court Filing

Core News & Articles

- Reuters

Core News & Articles

- Reuters

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION